Menu
Curie Logo
Donate
  • Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

194 result(s)

  • Breast cancer
    Paris, Saint-Cloud
    TOPOLOGY
    A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    BO25430
    AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY.

    FLORENCE LEREBOURS

  • Breast cancer
    Paris
    BRAINSTORM
    A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program

    EDITH BORCOMAN

  • Saint-Cloud
    BYLieve (CBYL719X402)
    A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

    FLORENCE LEREBOURS

  • Leukemia
    Saint-Cloud
    Backbone Inter-Group-1 (BIG-1)
    Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

    JACQUES VARGAFTIG

  • Lymphoma
    Saint-Cloud
    CA-4948-101
    An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.

    CAROLE SOUSSAIN

  • Lymphoma
    Saint-Cloud
    CA073-1020
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

    CLEMENTINE SARKOZY

  • Hématologie / cancers du sang
    Saint-Cloud
    CA073-1022
    Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced-Stage Follicular Lymphoma (GOLSEEK-2)"

    CLEMENTINE SARKOZY

  • Paris
    CA245-0001
    Phase 3, randomized, double-blind, multicenter study evaluating the combination of BMS-986489 (a fixed-dose combination of Nivolumab and BMS-986012) with carboplatin and etoposide versus the combination of Atezolizumab with carboplatin and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC).

    NICOLAS GIRARD

  • Breast cancer
    Saint-Cloud
    CAAA603B12101 NeoB
    Phase Ib Dose Finding Study Assessing Safety and Activity;of [;177Lu]LuNeob in combination with ribocilcib and fulvestrant;in subjects with HR positive, HER2 negative breast cancer,;experiencing early relapse from (neo)adjuvant endocrine;therapy.

    CAPUCINE RICHARD

  • Cancers urogénitaux
    Paris, Saint-Cloud
    CAAA617D12302
    A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

    CAPUCINE RICHARD

  • Breast cancer
    Paris, Saint-Cloud
    CAMBRIA-2
    CAMBRIA-2: A Phase III, Randomised, Open-label Study to Evaluate the Efficacy and Safety of Camizestrant (AZD9833), a Next Generation Oral Selective Estrogen Receptor Degrader (ngSERD), Compared with Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment in Patients with Estrogen Receptor-positive, HER2-negative Early Breast Cancer at Medium to High or High Risk of Recurrence, Who Have Completed Definitive Locoregional Therapy and Have No Evidence of Disease.

    PAUL-HENRI COTTU, FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    CANTO (Saint-Cloud)
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

    FLORENCE LEREBOURS

  • Saint-Cloud
    CANTO BIS
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

    FLORENCE LEREBOURS

  • Breast cancer
    Paris, Saint-Cloud
    CAPPA
    Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

    DELPHINE LOIRAT

  • Childhood and adolescent cancers
    Paris
    CDRB436G2401
    An open label, multi-center roll-over study to assess longterm;effect in pediatric patients treated with Tafinlar;(dabrafenib) and/or Mekinist (trametinib)

    ISABELLE AERTS GAJDOS

  • Paris
    CINNAMON
    Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial.

  • Digestive cancers
    Saint-Cloud
    CL1-95029-002
    Open-label, non-randomized, Phase 1b/2 trial investigating the;safety, tolerability, and antitumor activity of S095029 (anti-;NKG2A antibody) as a part of combination therapy in participants;with locally advanced and unresectable or metastatic MSIH/;dMMR gastroesophageal junction /gastric cancer

  • Paris
    CLEVER-PEPTIDE (IC 2018-06)
    Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer.

    CHRISTOPHE LE TOURNEAU

  • Lung cancer
    Paris
    COCOON
    A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

    ELISA GOBBINI

  • Tumeurs du système nerveux central
    Paris, Saint-Cloud
    COG-PROTON-01
    Long-term cognitive and functional impact of proton-therapy or modern fractionated radiotherapy in cavernous sinus meningioma: An open-label randomized 1:1 phase III study

    EMMANUEL JOUGLAR, MAXIME LOO

  • Cancers gynécologiques
    Paris, Saint-Cloud
    COLIBRI- 2
    Phase·Ib/II, multicenter, open-label study evaluating BDC-1001, a HER2-targeted TLR7/8 agonist antibody-drug conjugate, as monotherapy and in combination with nivolumab in advanced HER2-expressing solid tumors.

    HELENE SALAUN

  • Saint-Cloud
    CONTESSA - ODO-TE-B301
    Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

    ETIENNE BRAIN

  • Paris
    CP-START 001
    Open-label, First-in-Human, Phase 1/2 Study with Dose Escalation and Expansion of STAR0602, a Bifunctional Antibody Fusion Targeting Selective T Cell Receptors (TCR), in Patients with Unresectable, Locally Advanced, or Metastatic Antigen-Rich Solid Tumors (START-001).

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    CRISP (IC 2017-08 / ITCC 053)
    A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies.

    ISABELLE AERTS GAJDOS

  • Breast cancer
    Saint-Cloud
    CT7001_003 (SUMIT ELA)
    A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    CodeBreak202
    A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202)

    NICOLAS GIRARD

  • Saint-Cloud
    D7407C00001- SOUNDTRACK-E
    A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    DOLAF
    An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib

  • Lung cancer
    Paris
    DS1062-A-U303/ TROPION-Lung07
    A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)

    NICOLAS GIRARD

<
1 2...7
>